Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2020 20:48 ET | Source: Kezar Life Sciences, Inc.

Kezar Announces Pricing of a Public Offering of $46.7 million of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
June 08, 2020 06:00 ET | Source: Kezar Life Sciences, Inc.

Kezar Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
June 03, 2020 16:02 ET | Source: Kezar Life Sciences, Inc.

Kezar Provides Data Update from MISSION Study of KZR-616

Two of two patients with Lupus Nephritis saw greater than 50% reduction in proteinuriaKZR-616 demonstrates improvement on exploratory efficacy measures across seven measures of disease activity...
May 28, 2020 16:01 ET | Source: Kezar Life Sciences, Inc.

Kezar Life Sciences to Participate in Fireside Chat During the Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to...
May 20, 2020 16:41 ET | Source: Kezar Life Sciences, Inc.

Kezar Announces Presentations During Upcoming Scientific Conferences

SOUTH SAN FRANCISCO, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
May 07, 2020 16:01 ET | Source: Kezar Life Sciences, Inc.

Kezar Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update

Noreen R. Henig, MD appointed as Chief Medical OfficerAdditional data from the ongoing Phase 1b portion of the MISSION study to be presented before the end of Q2 2020IND submission for KZR-261, a...
May 04, 2020 16:01 ET | Source: Kezar Life Sciences, Inc.

Kezar Life Sciences Strengthens Executive Team with the Appointment of Noreen R. Henig, MD as Chief Medical Officer

SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat...
April 09, 2020 07:00 ET | Source: Kezar Life Sciences, Inc.

Kezar Provides Statement Regarding COVID-19 Pandemic

SOUTH SAN FRANCISCO, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
March 12, 2020 16:01 ET | Source: Kezar Life Sciences, Inc.

Kezar Life Sciences Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update

Phase 2 MARINA, MISSION and PRESIDIO trials with KZR-616 are progressingAdditional data from the ongoing Phase 1b portion of the MISSION study to be presented during various medical conferences...
February 26, 2020 16:01 ET | Source: Kezar Life Sciences, Inc.

Kezar Life Sciences to Present at Cowen and Company’s 40th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...